Intensification of free radical oxidation of low-density lipoproteins in the plasma of patients with ischemic heart disease receiving beta-hydroxy-beta-methylglutaryl-coenzyme A reductase inhibitor cerivastatin and inhibition of low-density lipoprotein peroxidation with antioxidant probucol.

Abstract

Inhibitors of the key enzyme of cholesterol biosynthesis beta-hydroxy-beta-methylglutaryl-coenzyme A reductase (statins) decrease cholesterol content in atherogenic low-density lipoproteins in patients with coronary heart disease and hypercholesterolemia, but inhibited biosynthesis of ubiquinone Q10 protecting low-density lipoproteins from free radical oxidation. Cerivastatin in a daily dose of 0.4 mg markedly increased the content of lipid peroxides in low-density lipoproteins. However, complex therapy with cerivastatin and antioxidant probucol (250 mg/day) was accompanied by a sharp decrease in the content of lipid peroxides in low-density lipoproteins in patients with coronary heart disease in vivo. These data indicate that antioxidant agents should be used in combination with inhibitors of beta-hydroxy-beta-methylglutaryl-coenzyme A reductase (hypolipidemic preparations) for the therapy of patients with coronary heart disease.

• Authors: V Z Lankin, A K Tikhaze, G G Konovalova, V S Tutunov, N V Medvedeva, T I Kotkina, V V Kukharchuk, Yu N Belenkov
• Journal: Bulletin of experimental biology and medicine (Bull Exp Biol Med) Vol. 134 Issue 1 Pg. 39-42 (Jul 2002) ISSN: 0007-4888 [Print] United States
• PMID: 12459865 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antioxidants
• Cholesterol, LDL
• Coenzymes
• Enzyme Inhibitors
• Free Radicals
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Lipoproteins, LDL
• Peroxides
• Placebos
• Pyridines
• Ubiquinone
• Cholesterol
• cerivastatin
• coenzyme Q10
• Probucol
• Oxygen

Topics

• Antioxidants (pharmacology)
• Cholesterol (metabolism)
• Cholesterol, LDL (blood, metabolism)
• Coenzymes
• Double-Blind Method
• Enzyme Inhibitors (pharmacology)
• Free Radicals
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (pharmacology)
• Hypercholesterolemia (drug therapy, metabolism)
• Lipid Metabolism
• Lipoproteins, LDL (metabolism)
• Male
• Middle Aged
• Myocardial Ischemia (blood)
• Oxygen (metabolism)
• Peroxides (metabolism)
• Placebos
• Probucol (pharmacology)
• Pyridines (pharmacology)
• Random Allocation
• Time Factors
• Ubiquinone (analogs & derivatives, metabolism, pharmacology)